Emerging Competition Issues Involving Follow-On Biologics

Darren Tucker joined V&E’s global antitrust practice as a partner in January 2018. Arriving from Morgan Lewis & Bockius LLP, he brings valuable insights to clients regarding competition enforcement and policy issues.

In this article Tucker examines the ways in which pharmaceutical firms have allegedly delayed product entry in violation of the antitrust laws and whether this conduct is likely to occur in the context of biologics and how the antitrust analysis of this conduct may differ for biologics.

Key Contacts

Partner

Darren Tucker

+1.202.639.6553

darrentucker@velaw.com

Related Insights

V&E⁺

Pipeline to Victory: How V&E Scored a Major Jury Trial Win for Antero Resources

April 3, 2020
V&E⁺

The Home Court: Inside V&E's Own Courtroom

March 31, 2020
V&E⁺

Business Interruption Insurance and COVID-19: 5 Things You Should Know

March 25, 2020
Coronavirus: Preparation & Response

SEC Offers Filing Extensions Amid Coronavirus Pandemic

V&E SEC Update

March 9, 2020

This information is provided by Vinson & Elkins LLP for educational and informational purposes only and is not intended, nor should it be construed, as legal advice.